Sequenom Announces Appointment Of Bill Bowen To Senior Vice President And General Counsel
SAN DIEGO, Oct. 11, 2012 /PRNewswire/ -- Sequenom, Inc. (SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the appointment of Bill Bowen as Senior Vice President and General Counsel. Mr. Bowen will report to Dr. Harry F. Hixson, Chairman and CEO and will be responsible for all company legal and patent activities.
"With Mr. Bowen's extensive expertise in biotechnology and medical device corporate counsel, he brings the critical skills to help guide the company with strategic legal and patent strategies as we continue to evolve our offerings in the genetic analysis marketplace," said Harry F. Hixson, Jr., Ph.D., chairman and chief executive officer. "By having Bill join us, Sequenom gains a leader who has experience in the diagnostics environment with a company that has been on a growth track similar to the one that we are on currently."
Mr. Bowen was previously employed with Gen-Probe Incorporated, a San Diego-based molecular diagnostics company, where he served as Senior Vice President and General Counsel. Prior to joining Gen-Probe, Mr. Bowen was a business litigation partner at Luce Forward Hamilton & Scripps, LLP. Mr. Bowen received his J.D. from the University of Virginia, School of Law and a bachelor's degree in management from the University of Virginia.
Sequenom, Inc. is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
SOURCE Sequenom, Inc.